1/6
08:37 am
rnaz
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma [Yahoo! Finance]
Medium
Report
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma [Yahoo! Finance]
1/6
08:01 am
rnaz
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
Medium
Report
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
12/22
08:39 am
rnaz
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors [Yahoo! Finance]
Medium
Report
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors [Yahoo! Finance]
12/22
08:01 am
rnaz
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
Medium
Report
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
12/11
08:05 am
rnaz
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
High
Report
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
11/17
08:41 am
rnaz
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer [Yahoo! Finance]
Low
Report
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer [Yahoo! Finance]
11/17
08:01 am
rnaz
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
Low
Report
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
10/25
12:13 pm
rnaz
TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.